The cardiovascular effects of the beta-adrenergic blocking agent, sotalol, have been assessed in a group of patients with heart disease. There was a significant reduction in heart rate and cardiac output, but stroke volume was unchanged. Systemic arterial and pulmonary artery pressures were not significantly altered. Indices of mryocardial function (dp/dt max and V max) were also significantly reduced.
Though previous studies have reported that sotalol is devoid of myocardial depression associated with other beta-adrenergic blocking drugs, these results suggest that sotalol has both a negative chronotropic and a lesser negative inotropic action.
Beta-adrenergic blocking drugs are now widely used in clinical cardiology. In addition to beta-adrenergic blockade, however, undesirable effects such as myocardial depression may occur (Nakano and Kusakari, I966;  Blinks, I967). Sotalol (M.J., i999)l has been reported to be a beta-adrenergic blocking agent devoid of significant myocardial depression (Lish, Weikel, and Dungan, 1965; Levy and Richards, I965) . Though studies of sotalol in man have been reported (Brooks et al., 1970; Svedmyr, Malmberg, and Haggendal, I970) , little is known of the effect of this drug on myocardial contractility in patients with heart disease. The purpose of the present study was to assess the cardiovascular effects of sotalol with particular reference to myocardial contractility.
Methods
Twelve patients, aged 24 to 52 years, were studied in the fasting state during cardiac catheterization carried out for diagnostic purposes and assessment for cardiac surgery (Table i) . Each patient gave permission for the use of sotalol. None of the patients was in cardiac failure at the time of the study. The effect of sotalol was investigated in 2 groups of 6 patients. The first group had haemodynamic measurements made before and after sotalol administration. Four of these patients were in sinus rhythm and 2 were in atrial fibrillation, receiving digoxin therapy. The second group had studies of myocardial contractility performed. All of these patients were in sinus rhythm and none was receiving digoxin. In each group sotalol was administered intravenously in a dosage of o-2 mg/kg body weight.
The heart rate was obtained from a continuously recorded electrocardiogram. Pulmonary artery pressure was recorded using a Goodale- 
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Since changes in myocardial contractility may be rate related, it was necessary to maintain a constant heart rate before and after sotalol administration. This was done by atrial pacing using a NBIH bipolar pacing catheter' introduced from an antecubital vein and positioned at the superior vena cava-right atrial junction. Throughout the study, the heart rate was maintained at I0 beats a minute above its resting level. Left ventricular pressure was measured from a Gensini catheter introduced retrogradely through the aortic valve. The first derivative of left ventricular systolic pressure was measured electronically using a differentiating circuit (Sanborn 350-i6 pressure derivative) and the maximum value recorded -LV dp/dt max. Left ventricular end-diastolic pressure and the first derivative of left ventricular systolic pressure were recorded at a paper speed of 200 mm/sec and the isovolumic segment of the left ventricular pressure tracing was used to calculate force velocity curves from the formula (Mason, I969) :
LV dp/dt sec' K.P.+C where P = LV pressure (mmHg) LV dp/dt=simultaneously measured rate of rise of LV pressure (mmHg). K and C are constants (K = 40: C = 8o) (Parmley and Sonnenblick, I967 An index of the contractile state of the myocardium was then obtained by extrapolation of the isovolumic segment of the force velocity curve back to zero pressure load -this value being described as V max.
Results
Haemodynamic results are shown in Table 2 . Heart rate decreased significantly during the study from a control value of 83 ± 6 beats a minute to 69 ± 5 beats a minute. The cardiac output fell significantly from 50 ± _03 l./min to 3.9 ± 0.2 1./min while the stroke volume was unchanged, suggesting that the decrease in cardiac output was rate related. The mean systemic arterial pressure fell slightly but not significantly and the mean pulmonary artery pressure was unaltered. There was a significant reduction in the derived variable of external cardiac work and a rise of approximately 25 per cent in systemic vascular resistance after sotalol administration. The changes in left ventricular dp/dt max and V max are shown in Table 3 and Fig. I , 2, and 3. There was a significant reduction in both variables. There I The effect of intravenous adm, tion of sotalol on the dp/dt (max).
was a small but non-significant inci left ventricular end-diastolic pressu 6-4±2-I to 7-2 ± I *6 mmHg. uri and lol were due to a negative chronotropic action. )65) and They reported that sotalol did not have any of myo-negative inotropic action though this finding studying was mainly based on a study of anaesthetized, a. Blinks apparently healthy, dogs. hat sotaIn the present study the intravenous adyocardial ministration of sotalol to a group of patients tthough with valvular heart disease of varying severity 1. Brooks (Table 2) but free from cardiac failure resulted talol in a in a significant fall in heart rate and cardiac ic heart output, while changes in stroke volume, mean ding pa-systemic arterial pressure, and pulmonary hey sug-artery pressure were slight and not significant. of sota-These results are consistent with a negative chronotropic action in keeping with a beta-.inistra .
adrenergic blocking drug but differ from the -haemodynamic changes found after propranolol (Sowton and Hamer, 1966) , where a fall in stroke volume as well as cardiac output occurred. The increase in the calculated systemic vascular resistance found after sotalol is thought possibly to be secondary to reflex vasoconstriction in response to the decrease in cardiac output.
These data do not provide definitive evidence of the effect of sotalol on myocardial contractility. Furnival, Linden, and Snow (1970) suggested that the dp/dt max is a quantitative index of inotropic changes in the left ventricle and that though influenced by ventricular preload and after-load is useful in the -,----. assessment of directional changes of contracsotalol tility in response to an inotropic drug or other U'-4 79o Hutton, Lorimer, Hillis, McCall, Reid, and Lawrie intervention in an individual patient. Though there are a number of technical and theoretical limitations in the derivation of the velocity of shortening of the contractile element to zero load (V max), Falsetti et al. (I97i) assessed myocardial contractility by several methods and concluded that V max was the most sensitive. In the present series, the left ventricular pressure measurements were obtained from a fluid-filled catheter system similar to that used by Hugenholtz et al. (I970) who compared a fluid-filled catheter system with a catheter tipped transducer and obtained comparable values for dp/dt and V max. In the present study a constant heart rate was obtained by atrial pacing, thus allowing the effects of sotalol on myocardial contractility to be assessed independently of its negative chronotropic action. After injection of sotalol, the left ventricular end-diastolic pressure remained unchanged. There was, however, a reduction in myocardial contractility as shown by a significant decrease in left ventricular dp/dt max and a downward shift of the forcevelocity curve with a resultant fall in V max.
External cardiac work represents energy associated with myocardial shortening and is one of the factors determining myocardial oxygen consumption (Sonnenblick, Ross, and Braunwald, i968) . The significant reduction in external cardiac work in addition to the effect on the heart rate and the reduction in the velocity of myocardial contraction suggests that, in common with other beta-adrenergic blocking drugs, sotalol decreases myocardial oxygen consumption.
The above results are consistent with a betaadrenergic blocking drug which has a predominant rate-dependent effect but in addition has a modest depressant action on the myocardium. Further clinical evaluation of sotalol appears to be indicated.
